NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Pfizer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On October 26, 2022, Bloomberg reported that Italian authorities are investigating Pfizer for allegedly hiding profits of at least EUR1.2 billion by transferring money to business units in other countries, including the U.S. and the Netherlands, to avoid taxes. The probe began in February and covers 2017 through 2019.
On this news, Pfizer's stock price fell $0.32 per share, or 0.69%, to close at $45.74 per share on October 27, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980